Monthly Archives: September 2019

Donate Blood to Support Sickle Cell Patients

September is Sickle Cell Awareness Month; Red Cross blood and platelet donations needed for patients
This school year students battling sickle cell disease and childhood cancers prepare to face challenges in the classroom unknown to their healthy peers. Many will fall behind in coursework after missing weeks of school, require tutoring and special education services. But there is a way people can help ease the struggle of these serious diseases.
September is Sickle Cell Awareness Month, making it a great time to donate blood. The Red Cross, Sickle Cell Disease Association of America, Inc., and the Sickle Cell Foundation of Georgia, Inc. formed a partnership last year to increase blood donations to support the SCD community. Over the five-year partnership, the goal is to collect 15,000 blood donations. Donations like these are essential to students living with SCD who rely heavily on lifesaving blood and platelet donations from generous and diverse donors, to help keep them in the classroom. Schedule an appointment to give blood with the American Red Cross by visiting RedCrossBlood.org, using the Red Cross Blood Donor App, calling 1-800-RED-CROSS or activating the Blood Scheduling Skill for Amazon Alexa.
“Sickle cell disease and childhood cancer profoundly impact the lives of young people— ensuring there is a diverse and sufficient blood supply is critical to their survival and ability to get back to school,” said Dr. Yvette Marie Miller, executive medical director at the Red Cross. “The Red Cross encourages diverse blood donors to roll up a sleeve this September and throughout the year to help the many diverse patients in need of blood each day.”
Blood type, like eye color, is an inherited trait passed genetically from parents. The vast majority of blood types fall into one of the major ABO groups, but for some patients with rare blood types, blood must be matched closely, beyond the primary A, B, O and AB blood types, to reduce the risk of developing complications from transfusion therapy. A patient in need is more likely to find a compatible blood match from a donor of the same race or ethnicity.
Students with sickle cell disease admit it impacts performance
A recent study conducted by researchers from Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine indicates that 60% of participants reported that sickle cell disease interfered with their school performance and over 75% of participants diagnosed with the most severe sickle cell form reported receiving special education services due to absences.
Regular blood transfusions are one of the most common treatments for sickle cell disease, which have been proven to help patients by unblocking blood vessels, alleviating pain from a sickle cell crisis. Many patients require transfusions multiple times per year throughout their lifetime.
Braden Green suffered from Acute Chest Syndrome, the leading cause of death in sickle cell patients and needed blood transfusions to survive. During his recovery he missed six weeks of school and depended on instructors to help him get caught up.
His mom, Brenda Green, recalls watching the donated blood enter her son’s body. “I realized at that moment how important a blood donation is.” She vowed to become an advocate for blood donations and has since hosted several blood drives for patients in need.
“If it hadn’t been for that blood transfusion, I am not sure where we would be today.”
Blood donation information
All blood types are needed to ensure a reliable supply for patients. A blood donor card or driver’s license or two other forms of identification are required at check-in. Individuals who are 17 years of age in most states (16 with parental consent where allowed by state law), weigh at least 110 pounds and are in generally good health may be eligible to donate blood. High school students and other donors 18 years of age and younger also have to meet certain height and weight requirements.
Blood and platelet donors can save time at their next donation by using RapidPass® to complete their pre-donation reading and health history questionnaire online, on the day of their donation, before arriving at the blood drive. To get started, follow the instructions at RedCrossBlood.org/RapidPass or use the Red Cross Blood Donor App.
About the American Red Cross:
The American Red Cross shelters, feeds and provides emotional support to victims of disasters; supplies about 40 percent of the nation’s blood; teaches skills that save lives; provides international humanitarian aid; and supports military members and their families. The Red Cross is a not-for-profit organization that depends on volunteers and the generosity of the American public to perform its mission. For more information, please visit redcross.org or cruzrojaamericana.org, or visit us on Twitter at @RedCross.  

GBT and SCDAA to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

GlobalBlood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) announced that they will host the 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 10, 2019, at The Westin Washington, D.C. U.S. Representative Robin Kelly, chair of the Congressional Black Caucus Health Braintrust, will deliver the keynote address.
Taking place during National Sickle Cell Awareness Month, the SCD Therapeutics Conference will highlight the latest medical advances and future trends in the treatment of patients with SCD. In addition to Rep. Kelly’s keynote address, the program will feature panel discussions and presentations from leading physicians, patient advocates and healthcare policymakers on a range of issues and topics, including the impact of SCD on the brain and cognitive function and hot topics in SCD from the perspective of patients and caregivers. The Conference will also feature updates from the American Society of Hematology Research Collaborative’s SCD Clinical Trials Network and the Sickle Cell Community Consortium, as well as presentations from biopharmaceutical industry leaders.
“We are honored to host, in partnership with the Sickle Cell Disease Association of America, the annual SCD Therapeutics Conference for the third year in a row, as it will bring together patient advocates, opinion leaders and clinical experts,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Support and collaboration across the broader community is essential as we work together to try to fundamentally transform how SCD is treated. We are optimistic that this year’s Conference will spur important discussions as we continue to pursue our shared mission of making a meaningful difference in the future of SCD care.”
“As co-hosts of the annual SCD Therapeutics Conference, we are thrilled to help advance meaningful discussions aimed at understanding and addressing the needs of the SCD community,” said Beverley Francis-Gibson, B.A., M.A., president and chief executive officer of SCDAA. “It is necessary that we continue to learn and grow based on the latest advancements that will be discussed at the Conference, in addition to understanding future issues and trends for treating patients with SCD.”
The 8th Annual SCD Therapeutics Conference will feature the following speakers and panelists:

  • Biree Andemariam, M.D., Associate Professor, Department of Medicine, University of Connecticut
  • Lakiea Bailey, Ph.D., Founder, Sickle Cell Community Consortium
  • Velvet Brown-Watts, Founder-Chairperson, Supporters of Families with Sickle Cell Disease
  • Chuck Chesson, Ph.D., Director, Sickle Cell Disease Clinical Trials Network
  • Jew-EL Darbone, Sickle Cell Patient Advocate
  • Jeremie Estepp, M.D., Medical Director, Clinical Translation Program in Hematology, St. Jude Children’s Research Hospital
  • Beverley Francis-Gibson, B.A., M.A., President and Chief Executive Officer, SCDAA
  • André Harris, CHW, Sickle Cell Patient Advocate
  • The Honorable Robin Kelly, Chair, Congressional Black Caucus Health Braintrust, United States House of Representatives
  • Allison King, M.D., M.P.H., Ph.D., Associate Professor of Occupational Therapy, Pediatrics, Medicine, Surgery (Prevention and Control) and Education,
  • Washington University School of Medicine
  • Hertz Nazaire, Sickle Cell Patient Advocate
    Additionally, multiple companies that are developing treatments for patients with SCD will present at the Conference. They include Addmedica, CRISPR Therapeutics/Vertex, Cyclerion, Emmaus Life Sciences, GBT, Imara and Sanofi. To ensure that those who are unable to attend the Conference can benefit from the presentations and information sharing, GBT is collaborating with Sickle Cell Warriors, an SCD community organization, to livestream from the Conference on the organization’s Facebook page at www.facebook.com/SickleCellWarriors. Following the event, GBT will post videos on its corporate YouTube channel. For more information about the Conference or to register to attend, visit http://www.scdconference.com.